Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Delcath Systems, Inc. (DCTH)

4.05   -0.06 (-1.46%) 09-29 16:00
Open: 4.1 Pre. Close: 4.11
High: 4.3399 Low: 4.03
Volume: 225,091 Market Cap: 62(M)

Technical analysis

as of: 2023-09-29 4:26:54 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 5.77     One year: 6.47
Support: Support1: 3.98    Support2: 3.31
Resistance: Resistance1: 4.94    Resistance2: 5.53
Pivot: 4.35
Moving Average: MA(5): 4.07     MA(20): 4.44
MA(100): 5.39     MA(250): 4.6
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 7.4     %D(3): 7.9
RSI: RSI(14): 39.5
52-week: High: 7.98  Low: 2.33
Average Vol(K): 3-Month: 2,372 (K)  10-Days: 275 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ DCTH ] has closed above bottom band by 23.0%. Bollinger Bands are 34.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.35 - 4.37 4.37 - 4.39
Low: 3.97 - 4 4 - 4.02
Close: 4.01 - 4.05 4.05 - 4.09

Company Description

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Headline News

Wed, 27 Sep 2023
Delcath Systems Reports Inducement Grants Under Nasdaq Listing ... - PR Newswire

Tue, 19 Sep 2023
Delcath Systems Inc (DCTH) Up 4.55% in Premarket Trading - InvestorsObserver

Sat, 09 Sep 2023
A Retrospective Comparative Study of Chemosat and SIRT ... - PR Newswire

Thu, 07 Sep 2023
Canaccord Genuity Maintains Delcath Systems (DCTH) Buy ... - Nasdaq

Tue, 05 Sep 2023
Delcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023 - Yahoo Finance

Fri, 01 Sep 2023
Delcath Systems, Inc. Announces Additional $35 Million in Funding ... - PR Newswire

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Medical Devices
Shares Out. -11 (M)
Shares Float 0 (M)
% Held by Insiders 1.528e+007 (%)
% Held by Institutions 1.059e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS 2.03e+006
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -3
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 226.7
Return on Equity (ttm) -96.1
Qtrly Rev. Growth 696.8
Gross Profit (p.s.) 0.19
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -3.219e+007
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio 0
PEG Ratio -0.2
Price to Book value -1.36
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 957710
Forward Dividend 530790
Dividend Yield 23647200%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.